Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2016 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. Look for comparisons against own past, already real and recurring, and early stage. Scan transcript for relevant statements. Vic Richey and Gary Muenster discuss various segments. Key points: technical packaging, Plastique, Fremont, Doble, Test, VACCO, aerospace. Look for any mention of deal size, order size, contract size, project size increasing. There is mention of "longer term LTAs" in packaging, but that's about contract duration, not size. Also "we have identified some solid upside opportunities" but not about size escalation. In Test, they mention opportunities in China, electric vehicles, but not that each deal is bigger. In aerospace, they mention A350 program running better than expected, but not that orders are larger. No explicit statement about progressive increase in unit size of deals. They talk about growth, but not about individual engagements being larger than before. They mention "we are well ahead of our near term order and production plan on several platforms led by the A350" but that's about volume. Also, they mention "the early performance of Plastique is consistent with our acquisition forecast" but not about deal size. No mention of "largest order ever" or "average order size increasing". So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.